Table 1.
Baseline characteristics of patients according to treatment arm
| HIV-negative | HIV-positive | |||
|---|---|---|---|---|
| Arm A | No HAART Arm B |
NRTI-containing Arm C1 |
NRTI-free Arm C2 |
|
| n = 50 | n = 49 | n = 49 | n = 20 | |
| Age [years]** | 41 (25 - 55) | 39 (24 - 47) | 42 (30 - 47) | 43 (34 - 61) |
| Male sex* [%] | 60 | 74 | 76 | 85 |
| Transmission risk [%] | ||||
| IVDU | 40 | 33 | 25 | 5 |
| Blood products | 10 | 2 | 8 | - |
| Sexual | 8 | 2 | 10 | 10 |
| other | 8 | 2 | - | - |
| unknown/missing | 34 | 61 | 57 | 85 |
| HCV-genotype [%] | ||||
| 1 | 52 | 51 | 51 | 50 |
| 2 | 6 | 8 | 4 | 5 |
| 3 | 38 | 27 | 31 | 40 |
| 4 | - | 8 | 10 | 5 |
| other | 4 | 4 | 2 | - |
| untypable | - | 2 | 2 | - |
| HCV-RNA [IU/ml, log10] | 5.7 (4.5 - 6.8) | 5.7 (4.1 - 6.7) | 5.5 (4.4 - 6.8) | 5.9 (4.3 - 7.3) |
| ≥ 500 000 IU/ml [%] | 56 | 57 | 41 | 65 |
| ALT [IU/l] | 61 (21 - 179) | 68 (17 - 212) | 71 (30 - 221) | 75 (26 - 231) |
| HAART [%] | ||||
| PI/NNRTI/3 × NUC | - | - | 57/29/12 | 95/5/0 |
| AZT | 33 | - | ||
| d4T | 18 | - | ||
| ABC | 31 | - | ||
| 3TC/FTC | 98 | - | ||
| TDF | 47 | - | ||
| HIV-RNA [copies/ml, log10]** | - | 3.9 (1.9 - 4.9) | 1.7 (1.7 - 3.5) | 1.7 (1.7 - 4.5) |
| CD4-cellcount | ||||
| [/μl]** | - | 580 (301 - 1042) | 491 (222 - 781) | 390 (152 - 846) |
| [%] | - | 27 (15 - 41) | 27 (13 - 40) | 22 (16 - 41) |
* Statistically significant difference comparing arm A with arms B and C (HIV-positive vs. HIV-negative)
** Statistically significant difference comparing arm B versus C1 versus C2
Data shown as percent of patients or median (95% range). NRTI nucleos(t)ide reverse transcriptase inhibitor, IVDU intravenous drug abuse, other double infections, e.g. genotype 1 and 2 infection; PI protease inhibitor containing HAART, NNRTI non-nucleoside reverse transcriptase inhibitor containing HAART, 3xNUC HAART based on at least 3 nucleos(t)ides, AZT zidovudine, d4T stavudine, ABC abacavir, TDF tenofovir DF